Coagulation factor testing is generally performed to identify the presence of coagulation activity in a person which is associated with the control of blood clotting. Coagulation factor assay testing helps in identifying low level of coagulation factor activity, which is associated with excess bleeding and reduced clot formation. On the other hand, high level of coagulation factor activity is linked with increased clot formation, also known as thrombosis. It acts as a barrier during thromboembolism. Coagulation factor assay tests are carried out to identify deficiency of certain factors associated with certain chronic and acute diseases. These factors include fibrinogen, Factor II, Factor III, and others.
Coagulation factor assay testing is also carried out to gauge the function of specific factors. It is conducted for individuals that have prolonged prothrombin time or partial thromboplastic time. Coagulation factor assay tests act as screening tools that help determine whether an individual is suffering with coagulation factor issue. These tests help in investigation when the patient shows signs and symptoms of a bleeding disorder caused by inherited coagulation factor deficiency. This deficiency may lead to bleeding gums and excessive bleeding from minor bruises due to Von Willebrand disease or hemophilia A.
Coagulation factor deficiency may develop in different manners, which could be a result of an inherited genetic disorder or any other disease. When more than one clotting factors decrease, it is associated with an acquired condition caused by chronic or acute forms of diseases such as disseminated cirrhosis, cancer, vitamin K deficiency, or blood transfusion of only red blood cells. Concentration of the factor that is to be analyzed is rate-limiting as compared to a competent system that utilizes clot formation. The determination of Factor VIII activity. Factor VIII testing is one of the most routinely carried out coagulation factor assays in the U.S. and Europe. Based on end-user, the global coagulation factor assay testing market can be segmented into hospitals, specialized clinics, diagnostic laboratories, and others.
The global coagulation factor assay testing market is expected to expand during the forecast period, due to increasing prevalence of blood clotting disorders worldwide and rising incidence of chronic diseases, which calls for regular coagulation factor testing. Technological advancements in diagnostics have led to rapid test results and efficient diagnosis based on these results. This development has raised the demand for point-of-care assays in developed and developing countries, which has resulted in rise in testing for coagulation factor at home care settings. Key players are focused on enhancing their market penetration in new geographies through development of new products and mergers and acquisitions, thereby increasing their share in the global coagulation factor assay testing market. For instance, in September 2017, Sysmex Corporation announced the launch of Revohem FVIII Chromogenic, a coagulation factor VIII assay reagent that can be used with Sysmex’s automated blood coagulation analyzers.
Major restraints for the global coagulation factor assay testing market are lack of awareness in developing countries, regulatory constraints associated with point–of-care testing, lack of skilled professionals to perform tests in home care settings, and high cost of coagulation factor assay testing.
The global coagulation factor assay testing market has been divided into five regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America region is anticipated to hold a major market share during the forecast period, owing to developed health care infrastructure, high awareness, presence of major market players, favorable reimbursement scenario, and large number of patients suffering from blood disorders. Asia Pacific is expected to be a rapidly expanding market for coagulation factor assay testing, primarily due to increasing awareness, rising adoption of latest technologies, and improving health care infrastructure in the region. Latin America and Middle East & Africa are anticipated to provide lucrative growth opportunities to the coagulation factor testing market during the forecast period.
Major players in the global coagulation factor assay testing market are Abbott, Becton Dickinson, Beckman Coulter/Danaher, Grifols, Roche, Thermo Fisher Scientific, and Accriva.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
The regional analysis covers:
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.